We are an independent, global specialist HIV company that are committed to delivering innovative new options for the care and treatment of people living with HIV/AIDS.
Established in 2009 through a unique partnership between GSK and Pfizer, ViiV Healthcare combines the HIV expertise of GSK, Pfizer and Shionogi, who joined in 2012 following a long-term collaboration on the joint development of several novel integrase inhibitors.
Our current portfolio of twelve HIV treatments generated annual sales of £2.3 billion in 2015 providing us with the financial stability to take a sustainable, long-term view when investing in our pipeline of new medicines. Our scientists are 100% dedicated to finding new ways to limit the impact of HIV on the 36.9 million people living with the virus and understanding how best to prevent and treat the disease. Find out more about our commitment to R&D.
Our dedicated staff of more than 700 people work in 15 countries. We extend this geographical reach still further via our relationship with GSK to establish a presence in more than 65 countries around the globe. We are equipped to move quickly in response to the needs of the HIV community and have launched industry-leading access initiatives to help deliver on World Health Organisation/UNAIDS goals to reach all those who need treatment. Find out more about our innovative and sustainable approach to access.
In addition, we actively support community initiatives in HIV, including our Positive Action programmes, by partnering with like-minded organisations that share our ethos.
Learn more about us in our company brochure.